Tharimmune Presents Phase 1 Data On TH104 For Moderate-To-Severe Pruritus In Chronic Liver Disease At ACG 2024; No Opioid Withdrawal Effects Observed, Supporting Safety Profile With Phase 2 Results Expected In 2025
Portfolio Pulse from Benzinga Newsdesk
Tharimmune presented Phase 1 data on TH104 for treating moderate-to-severe pruritus in chronic liver disease at ACG 2024. The data showed no opioid withdrawal effects, supporting a favorable safety profile. Phase 2 results are expected in 2025.
October 28, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tharimmune's Phase 1 data for TH104 indicates a favorable safety profile with no opioid withdrawal effects, which is positive for the company's drug development pipeline. Phase 2 results are anticipated in 2025.
The Phase 1 data presentation at ACG 2024 highlights the safety of TH104, a key factor for investor confidence. The absence of opioid withdrawal effects is particularly positive, as it suggests a safer profile for patients. The anticipation of Phase 2 results in 2025 keeps the stock in focus for future developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90